|

Eribulin Clinical Trials

17 actively recruiting trials across 10 locations

Also known as: E 7389, E-7389, ER 086526, ER-086526, ER086526 +3 more

Pipeline

Phase 1: 2Phase 2: 7Phase 3: 5Phase 1/2: 3

Top Sponsors

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2
  • Washington University School of Medicine1
  • University of Washington1
  • Sun Yat-sen University1
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer17
  • Breast Cancer15
  • Metastatic Breast Cancer3
  • HER2-negative Breast Cancer2
  • Advanced Breast Cancer2

Other7 trials

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Phase 2
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Phase 3
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1/2
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3

Phoenix, Arizona1 trial

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Mayo Clinic Scottsdale - PPDS

Phase 3

Scottsdale, Arizona1 trial

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

Tucson, Arizona1 trial

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

The University of Arizona Cancer Center - North Campus

Phase 1/2

Springdale, Arkansas1 trial

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Highlands Oncology Group

Phase 3

Aurora, Colorado1 trial

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

University of Colorado

Phase 2

Miami, Florida1 trial

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

BAPTIST ALLIANCE - MCI (Data Collection Only)

Phase 2

Boston, Massachusetts1 trial

Scalp Cooling in MBC

Brigham and Women's Hospital

Phase 2

St Louis, Missouri1 trial

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Washington University School of Medicine

Phase 1

Houston, Texas1 trial

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

M D Anderson Cancer Center

Phase 1

Seattle, Washington1 trial

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.